| Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer AS Mansfield, MC Aubry, JC Moser, SM Harrington, RS Dronca, SS Park, ... Annals of Oncology 27 (10), 1953-1958, 2016 | 335 | 2016 |
| MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate AS Ireland, AM Micinski, DW Kastner, B Guo, SJ Wait, KB Spainhower, ... Cancer cell 38 (1), 60-78. e12, 2020 | 295 | 2020 |
| Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011 EAL Enninga, JC Moser, AL Weaver, SN Markovic, JD Brewer, ... Cancer medicine 6 (10), 2203-2212, 2017 | 130 | 2017 |
| Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab JC Moser, D Chen, S Hu‐Lieskovan, KF Grossmann, S Patel, SV Colonna, ... Cancer Medicine 8 (18), 7637-7643, 2019 | 57 | 2019 |
| The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma JC Moser, JS Pulido, RS Dronca, RR McWilliams, SN Markovic, ... Melanoma research 25 (1), 59-63, 2015 | 53 | 2015 |
| Regulation of pancreatic cancer growth by superoxide J Du, ES Nelson, AL Simons, KE Olney, JC Moser, HE Schrock, ... Molecular carcinogenesis 52 (7), 555-567, 2013 | 51 | 2013 |
| Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. WB McKean, JC Moser, D Rimm, S Hu-Lieskovan American Society of Clinical Oncology Educational book. American Society of …, 2020 | 48 | 2020 |
| Development and external validation of a prognostic nomogram for metastatic uveal melanoma S Valpione, JC Moser, R Parrozzani, M Bazzi, AS Mansfield, S Mocellin, ... PloS one 10 (3), e0120181, 2015 | 47 | 2015 |
| Pharmacological ascorbate and ionizing radiation (IR) increase labile iron in pancreatic cancer JC Moser, M Rawal, BA Wagner, J Du, JJ Cullen, GR Buettner Redox biology 2, 22-27, 2014 | 45 | 2014 |
| Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma JC Moser, G Wei, SV Colonna, KF Grossmann, S Patel, JR Hyngstrom Acta Oncologica 59 (4), 434-437, 2020 | 43 | 2020 |
| LBA O-9 Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer A Bullock, J Grossman, M Fakih, H Lenz, M Gordon, K Margolin, B Wilky, ... Annals of Oncology 33, S376, 2022 | 38 | 2022 |
| The mechanisms of action of Tumor Treating Fields JC Moser, E Salvador, K Deniz, K Swanson, J Tuszynski, KW Carlson, ... Cancer research 82 (20), 3650-3658, 2022 | 37 | 2022 |
| Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity M Arora, J Moser, TE Hoffman, LP Watts, M Min, M Musteanu, Y Rong, ... Cell 186 (12), 2628-2643. e21, 2023 | 25 | 2023 |
| Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated … AB El-Khoueiry, M Fakih, MS Gordon, AM Tsimberidou, AJ Bullock, ... Journal of Clinical Oncology 41 (4_suppl), LBA8-LBA8, 2023 | 21 | 2023 |
| c-Met expression and MET amplification in malignant pleural mesothelioma MC Bois, AS Mansfield, WR Sukov, SM Jenkins, JC Moser, CA Sattler, ... Annals of Diagnostic Pathology 23, 1-7, 2016 | 16 | 2016 |
| 479 Agen1181, an FC-enhanced anti-CTLA-4 antibody, alone and in combination with Balstilimab (anti-PD-1) in patients with advanced solid tumors: initial phase I results A El-Khoueiry, A Bullock, A Tsimberidou, D Mahadevan, B Wilky, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 12 | 2021 |
| Toward precision medicine in brain metastases AS Berghoff, PK Brastianos Seminars in neurology 38 (01), 095-103, 2018 | 11 | 2018 |
| Adjuvant therapy for resected high-risk melanoma. JC Moser, KF Grossman Seminars in cutaneous medicine and surgery 37 (2), 109-111, 2018 | 10 | 2018 |
| Mechanisms of resistance to PD-1 checkpoint blockade JC Moser, S Hu-Lieskovan Drugs 80 (5), 459-465, 2020 | 7 | 2020 |
| First-Line pembrolizumab therapy in a cisplatin-ineligible patient with plasmacytoid urothelial carcinoma: a case report L Hunter, J Moser, C Sturge, G Barraza, S Colonna Journal of Oncology Pharmacy Practice 26 (1), 216-219, 2020 | 7 | 2020 |
